🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Arun Azad

The University of Melbourne

ORCID: 0000-0001-7350-5622

Also affiliated with Peter MacCallum Cancer Centre

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study”.

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

International Journal of Cancer(2021)10.1002/ijc.33861
N/A
1.9DataRank · unranked
62 citations

Jean‐Yves Blay, Irene García, Johann S. De Bono, Christophe Le Tourneau, Víctor Moreno +25 more

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer

Prostate Cancer and Prostatic Diseases(2021)10.1038/s41391-021-00338-z
N/A
0DataRank · unranked
32 citations

Kevin Huynh, Manish Kohli, Winston Tan, Arun Azad, Nicole Yeung +12 more

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

EBioMedicine(2020)10.1016/j.ebiom.2020.102728
N/A
0DataRank · unranked
136 citations

Winston Tan, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calven Wong +10 more

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

EBioMedicine(2023)10.1016/j.ebiom.2023.104738
N/A
0DataRank · unranked
42 citations

Chao Dai, Edmond M. Kwan, Tiantian Zheng, Pan Du, Nicole Ng +12 more

1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2782
N/A
0DataRank · unranked
1 citations

Victor R. Lincha, Mohammad Hadigol, Justin Hoffman, N. Agarwal, N. Matsubara +5 more

HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101644
N/A
0DataRank · unranked
8 citations

Arun Azad, Mona Patel, Jason W.D. Hearn, Michele Wozniak, Fabian Zohren +5 more

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

BMC Medicine(2022)10.1186/s12916-022-02298-0
N/A
0DataRank · unranked
21 citations

Hui‐Ming Lin, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis +22 more